Eden Biodesign chosen for autoimmune project
Eden Biodesign, of Liverpool in the UK, a specialist provider of development and manufacturing services for new biopharmaceutical medicines, has been selected by the University of Birmingham to develop and produce vOX2:Fc, a novel therapeutic candidate for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
Eden Biodesign, of Liverpool in the UK, a specialist provider of development and manufacturing services for new biopharmaceutical medicines, has been selected by the University of Birmingham to develop and produce vOX2:Fc, a novel therapeutic candidate for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
The novel drug candidate is being investigated by Dr David Blackbourn and his research team and has already attracted interest from a number of biotech and pharmaceutical companies.
The project has been funded by the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA).
"Working with Eden Biodesign will allow us to advance our understanding of the therapeutic potential of this drug candidate; clinical applications for this novel therapy could range from autoimmune diseases such as rheumatoid arthritis to asthma and allergy," said Dr Blackbourn.